– Enlargement features a new 5-story, 136k sq. ft. multipurpose constructing in Sejong
– Greater than 300 new staff to be employed for the anticipated 2026 opening
RANCHO CORDOVA, Calif.–(BUSINESS WIRE)–SK pharmteco, a world contract growth and manufacturing group (CDMO), as we speak introduced a serious growth of its small molecule and peptide manufacturing capabilities with a $260 million funding to assemble a brand new state-of-the-art facility in Sejong, South Korea.
Scheduled to start operations in late 2026, the brand new facility would be the fifth plant the corporate opens in South Korea and shall be a cornerstone of SK pharmteco’s international manufacturing community. Spanning 135,800 sq. ft, it should characteristic eight manufacturing trains with an output of tens of metric tons yearly. This funding additionally consists of state-of-the-art peptide R&D amenities, cGMP kilo labs, and cGMP pilot plant for peptide manufacturing. These assets can assist early-stage scientific and industrial manufacturing with nice flexibility.
Final, the funding additionally consists of constructing the shell for a sixth manufacturing plant, which can enable us to shortly develop capability sooner or later.
This growth is a testomony to our unwavering dedication to serving the evolving wants of the life sciences trade,” said Joerg Ahlgrimm, CEO of SK pharmteco. “By investing on this new facility, we’re rising our capability in Asia according to our international growth technique and solidifying our place as a trusted accomplice for firms growing groundbreaking remedies, demonstrating our adaptability and reliability in a quickly altering trade.”
SK pharmteco plans to rent over 300 new staff on the Sejong web site to assist this growth. This funding underscores SK pharmteco’s dedication to assembly the rising demand for high-quality peptides and small molecules, important elements of many progressive therapies, demonstrating our reliability and dedication to the trade.
The life science trade is experiencing speedy progress, pushed by technological developments and a rising demand for progressive remedies. Nonetheless, the worldwide provide chain for these therapies faces challenges, together with restricted manufacturing capability and sophisticated regulatory necessities. SK pharmteco’s new facility addresses these challenges by offering a scalable and dependable answer for producing these essential therapies.
“Our new facility represents a significant investment in our future and a commitment to delivering exceptional value to our customers,” stated Yongwoo Park, SK pharmteco’s President, Small Molecule, Asia. “By expanding our capacity and capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality. This investment further solidifies SK pharmteco’s position as a trusted partner for companies developing innovative cell and gene therapies and small molecules, enabling us to accelerate the development and commercialization of life-changing treatments.”
About SK pharmteco
SK pharmteco is a world contract growth and manufacturing group (CDMO) with manufacturing websites, analysis & growth amenities, and analytical laboratories throughout the U.S., Europe, and Korea. The corporate companions with biopharmaceutical firms of all sizes to fabricate Energetic Pharmaceutical Components (API) and intermediates, cell and gene remedy applied sciences, registered beginning supplies, and analytical providers for the biopharmaceutical trade worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic funding firm for SK Group, South Korea’s second-largest conglomerate.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240929693295/en/
Keith Bowermaster, APR, CCMP
Communications Marketing consultant
keith.bowermaster@skpt.com
Web site: www.skpharmteco.com
Supply: SK pharmteco
